About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDNANCT02016222

Tear Analysis in the Diagnosis of Multiple Sclerosis

In the primary progressive multiple sclerosis, the detection of oligoclonal bands in cerebrospinal fluid is critical for the diagnosis. However, lumbar puncture for cerebrospinal fluid collection is c...

Lead sponsor: Lille Catholic University•13 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Lille Catholic University

Collaborators

Bayer

The objective of the present study is to assess concordance between oligoclonal bands detection in tears and in cerebrospinal fluid. We will include patients with primary progressive multiple sclerosis and we will compare results of oligoclonal bands detection by isoelectric focusing in cerebrospinal fluid and tears. Tears will be collected using a Schirmer strip. This would circumvent the practice of invasive lumbar punctures currently used in multiple sclerosis diagnosis.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•18 years old or more
•Progressive neurological deficit after 12 months
•At least 9 T2 brain lesions of minimum 3 mm evidenced by MRI and/or four or more T2 lesions of minimum 3 mm with positive Visual Evoked Potential and/or positive spinal cord MRI (at least two focal T2 lesions)

Exclusion Criteria

•Asiatic persons
•recurrent forms of the disease
•Persons wearing contact lenses
•Ocular Infection
•Corticoid treatment at least 30 days before sampling
•immunosuppressive or immunomodulatory treatment 3 months before sampling

Related studies

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

NCT07426991 · Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, and more

Active Not RecruitingPhase 2

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

NCT05893225 · Multiple Sclerosis, Primary Progressive Multiple Sclerosis, and more

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

NCT05974852 · Primary Progressive Multiple Sclerosis

COMPLETEDPhase 1

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289 · Primary Progressive Multiple Sclerosis

COMPLETEDPhase 3

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051 · Primary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 11, 2026Terms

Trial snapshot

StatusTERMINATED

PhaseNA

Enrollment80

Start dateApr 2011

Last updatedJun 11, 2026

Condition

Primary Progressive Multiple Sclerosis

Locations shown

Centre hospitalier universitaire (CHU), Nice

Nice, Alpes Maritimes

Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)

Lille, Nord

Centre hospitaliere universitaire

Bordeaux

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 11, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions